Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Non-Current Deffered Revenue: 2021-2024

  • ProQR Therapeutics N.V's Non-Current Deffered Revenue fell 33.83% to $31.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $31.4 million, marking a year-over-year decrease of 33.83%. This contributed to the annual value of $31.4 million for FY2024, which is 34.18% down from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Non-Current Deffered Revenue stood at $31.4 million for Q4 2024, which was down 33.83% from $47.5 million recorded in Q4 2023.
  • ProQR Therapeutics N.V's 5-year Non-Current Deffered Revenue high stood at $66.9 million for Q4 2022, and its period low was $16.8 million during Q4 2021.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $47.5 million (2023), whereas its average is $48.6 million.
  • In the last 5 years, ProQR Therapeutics N.V's Non-Current Deffered Revenue surged by 298.15% in 2022 and then slumped by 33.83% in 2024.
  • ProQR Therapeutics N.V's Non-Current Deffered Revenue (Quarterly) stood at $16.8 million in 2021, then soared by 298.15% to $66.9 million in 2022, then fell by 28.96% to $47.5 million in 2023, then crashed by 33.83% to $31.4 million in 2024.
  • Its Non-Current Deffered Revenue stands at $31.4 million for Q4 2024, versus $47.5 million for Q4 2023 and $66.9 million for Q4 2022.